Squarepoint
ZNTL icon

Squarepoint’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Squarepoint’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.8K Sell
30,691
-77,043
-72% -$199K ﹤0.01% 4116
2025
Q4 		$145K Buy
107,734
+86,412
+405% +$126K ﹤0.01% 3957
2025
Q3 		$32.2K Sell
21,322
-25,139
-54% -$37.7K ﹤0.01% 4264
2025
Q2 		$53.9K Sell
46,461
-2,641
-5% -$3.48K ﹤0.01% 4293
2025
Q1 		$78.1K Sell
49,102
-1,654
-3% -$3.57K ﹤0.01% 4277
2024
Q4 		$154K Sell
50,756
-64,349
-56% -$211K ﹤0.01% 4565
2024
Q3 		$424K Sell
115,105
-33,650
-23% -$122K ﹤0.01% 3222
2024
Q2 		$608K Buy
148,755
+125,649
+544% +$1.4M ﹤0.01% 2927
2024
Q1 		$364K Buy
+23,106
New +$318K ﹤0.01% 3261
2023
Q4 		– Sell
-45,473
Closed -$912K – 4587
2023
Q3 		$912K Sell
45,473
-34,639
-43% -$879K ﹤0.01% 2394
2023
Q2 		$2.26M Buy
80,112
+63,218
+374% +$1.52M 0.01% 1582
2023
Q1 		$291K Buy
+16,894
New +$342K ﹤0.01% 2591
2022
Q4 		– Sell
-29,269
Closed -$634K – 3680
2022
Q3 		$634K Buy
+29,269
New +$800K ﹤0.01% 2083
2022
Q2 		– Sell
-20,679
Closed -$954K – 3480
2022
Q1 		$954K Buy
20,679
+16,091
+351% +$868K ﹤0.01% 1619
2021
Q4 		$386K Buy
+4,588
New +$355K ﹤0.01% 2314
2021
Q3 		– Sell
-19,577
Closed -$1.04M – 3507
2021
Q2 		$1.04M Buy
+19,577
New +$1.05M ﹤0.01% 1602
2021
Q1 		– Sell
-10,825
Closed -$562K – 3694
2020
Q4 		$562K Buy
+10,825
New +$488K ﹤0.01% 1731

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Squarepoint's ZNTL Position: Q1 2026 in Review

Squarepoint reduced its Zentalis Pharmaceuticals (ZNTL) stake by 72% in Q1 2026, selling an estimated $199K and leaving 30,691 shares worth $71.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4116.

Squarepoint first reported a position in ZNTL in Q4 2020 and has held it in 17 quarters since. The position peaked at $2.26M in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Squarepoint held 30,691 shares of Zentalis Pharmaceuticals worth $71.8K as of Q1 2026.
  • Squarepoint sold 77,043 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $199K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4116 holding.
  • Squarepoint first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • Squarepoint's Zentalis Pharmaceuticals position peaked at $2.26M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.